News | Heart Failure | November 09, 2022

New Analysis of SOLOIST-WHF Results Demonstrates Sotagliflozin’s Significant Effect in Reducing the Risk of Hospital Readmissions for Heart Failure

Risk Reductions of 46% to 52% for Heart Failure Readmissions and for Composite of CV Death and Heart Failure Readmissions at 30- and 90-Days Following Hospital Discharge 

Risk Reductions of 46% to 52% for Heart Failure Readmissions and for Composite of CV Death and Heart Failure Readmissions at 30- and 90-Days Following Hospital Discharge

November 9, 2022 —  Lexicon Pharmaceuticals, Inc. announced that a new analysis of results from the SOLOIST-WHF Phase 3 outcomes study of its investigational heart failure treatment sotagliflozin, was presented at the American Heart Association Scientific Sessions 2022 in Chicago, Illinois.  The oral presentation, titled “The effect of the dual SGLT1 and 2 inhibitor sotagliflozin on cardiovascular mortality and hospital readmission rates for heart failure at 30- and 90-days post discharge in patients with type 2 diabetes hospitalized for worsening heart failure in the SOLOIST-WHF trial,” was delivered at 3:30pm CT this afternoon during the ‘Advances in Diabetes and Heart Failure: From Bench to Bedside’ session. 

Treatment with sotagliflozin demonstrated significant relative risk reductions of 46% to 52% for readmission for non-fatal heart failure events and for the composite of cardiovascular death and readmission for heart failure at 30- or 90-days following hospital discharge versus placebo. 

Heart failure is the number one cause of hospitalizations for Americans ages sixty-five years and older, with approximately one million hospitalizations for heart failure annually in the United States.  On average, twenty-five percent of patients will suffer another heart failure event and need to be readmitted to the hospital within 30 days of their initial discharge, and that number jumps to 65% of patients who will be readmitted within one year.  Heart failure cost burden is projected to reach nearly seventy billion dollars in the United States by the year 2030, with 80% of those total costs related to hospitalizations. 

“These results with sotagliflozin are meaningful for the patient, the caregiver, and the healthcare system overall,” said Bertram Pitt, M.D., FACC, professor of medicine emeritus at the University of Michigan, School of Medicine, and presenter of the results from the new analysis.  “Hospital readmissions are burdensome, time-consuming, and costly. This analysis provides evidence that sotagliflozin has the potential to address all of these concerns if administered to patients prior to or at hospital discharge after experiencing an episode of worsening heart failure.” 

“The SOLOIST-WHF trial continues to yield robust findings that further help characterize and differentiate the efficacy and safety profile of sotagliflozin in patients with acute or worsening heart failure,” said Dr. Craig Granowitz, Lexicon’s senior vice president and chief medical officer.  “Importantly, based on this new analysis by Dr. Bertram Pitt, sotagliflozin may reduce the likelihood of readmission rates for heart failure events and thus reduce the significant burden on patients, caregivers and the healthcare system.” 

About the SOLOIST-WHF Study 

SOLOIST-WHF was a multi-center, randomized, double-blinded, placebo-controlled Phase 3 study evaluating the cardiovascular efficacy of sotagliflozin versus placebo when added to standard of care in 1,222 patients with type 2 diabetes who had recently been hospitalized for worsening heart failure. The primary endpoint was the total number of events comprised of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure in patients treated with sotagliflozin compared with placebo. 

SOLOIST-WHF achieved its primary endpoint, with overall tolerability similar to placebo.  Results were presented at the Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions 2020 and simultaneously published in The New England Journal of Medicine (NEJM) in an article titled: “Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure” which may be accessed at www.nejm.org 

For more information: www.lexpharma.com 

More related content on AHA22  

New Analysis of Soloist-WHF Trial Underscores Sotagliflozin’s Effect on Reducing Recurrent Heart Failure Events 


Related Content

News | AHA

May 24, 2024 — The American Heart Association has issued a statement warning that false information about COVID ...

Home May 24, 2024
Home
News | AHA

February 9, 2024 — Injection of a substance to block an artery feeding the dura (protective sack around the brain) — ...

Home February 09, 2024
Home
News | AHA

February 8, 2024 — The American Heart Association (AHA), currently celebrating its centennial year, announced that it is ...

Home February 08, 2024
Home
News | AHA

February 8, 2024 — The latest late-breaking science from the second day of the American Stroke Association’s ...

Home February 08, 2024
Home
News | AHA

February 7, 2024 — According to results from a multi-center trial in the United States, called Zero Degree Head ...

Home February 07, 2024
Home
News | AHA

February 7, 2024 — Researchers presenting preliminary late-breaking science presented on the first day of the American ...

Home February 07, 2024
Home
News | AHA

February 7, 2024 — Eleven scientists leading the way in stroke research will be recognized during the American Stroke ...

Home February 07, 2024
Home
News | AHA

January 23, 2024 — Focused on delivering the latest scientific advancements and new treatments in cerebrovascular ...

Home January 22, 2024
Home
News | AHA

January 18, 2024 — A new American Heart Association (AHA) policy statement examines the history of structural racism ...

Home January 18, 2024
Home
News | AHA

November 13, 2023 — Vektor Medical, a pioneer in non-invasive arrhythmia analysis technology, is proud to highlight two ...

Home November 13, 2023
Home
Subscribe Now